- TRADE NAME: Sunosi (Jazz)
- INDICATIONS: A dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.
- SYNONYM: Sunosi
- CLASS: Dopamine reuptake inhibitor, Norepinephrine reuptake inhibitor
- HALF-LIFE: ~ 7 hours
- FDA APPROVAL DATE: 03/20/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Dopaminergic drugs, drugs that increase blood pressure and/or heart rate, monoamine oxidase (MAO) inhibitors - PREGNANCY: Available data from case reports are not sufficient to determine drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
